Evidence map›Paper›PMID 38822953›Full record

ArticleBreast cancer research and treatment2024

Universal genetic counseling in breast cancer patients significantly improves overall testing rates and improves completion rates in subpopulations.

Nora C Elson, Karen Wernke, Lauren M Yoder, Angela N Fellner, Kathleen M Raque, Anne M Kuritzky, Barbara A Wexelman

Abstract read
PubMed Publisher
In one paragraph

Article in Breast cancer research and treatment, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Nora C ElsonDivision of Breast Surgical Oncology, Department of Surgery, TriHealth Cancer Institute, 375 Dixmyth Avenue, Cincinnati, OH, 45220, USA. nora_elson@trihealth.com.ORCID http://orcid.org/0000-0001-6038-4761
Karen WernkeDepartment of Genetics, TriHealth Precision Medicine and Genetic Services Institute, Cincinnati, OH, USA.
Lauren M YoderDivision of Breast Surgical Oncology, Department of Surgery, TriHealth Cancer Institute, 375 Dixmyth Avenue, Cincinnati, OH, 45220, USA.
Angela N FellnerTriHealth Hatton Research Institute, Cincinnati, OH, USA.
Kathleen M RaqueDivision of Breast Surgical Oncology, Department of Surgery, TriHealth Cancer Institute, 375 Dixmyth Avenue, Cincinnati, OH, 45220, USA.
Anne M KuritzkyDivision of Breast Surgical Oncology, Department of Surgery, TriHealth Cancer Institute, 375 Dixmyth Avenue, Cincinnati, OH, 45220, USA.
Barbara A WexelmanDivision of Breast Surgical Oncology, Department of Surgery, TriHealth Cancer Institute, 375 Dixmyth Avenue, Cincinnati, OH, 45220, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe NCCN guidelines recommend genetic testing in those patients at increased risk of breast cancer in order to identify candidates for increased frequency of screening or prophylactic mastectomy. However, genetic testing may now identify patients who may benefit from recently developed targeted breast cancer therapy. In order to more widely identify these patients, we implemented genetic counseling for all patients diagnosed with breast cancer.

methodsIn 2021, all patients evaluated within a Midwestern community hospital system diagnosed with breast cancer were offered genetic counseling. This group of patients was compared to a cohort of patients in 2021 who were offered genetic counseling based on NCCN guidelines. With Pearson's chi square, Fisher's Exact test, Mann-Whitney U, and multivariate regression as appropriate, individual demographic data and genetic testing completion between 2019 and 2021 were evaluated.

resultsA total of 973 patients were reviewed. 439 were diagnosed with breast cancer in 2019 and 534 in 2021. Demographics and stage at diagnosis (p = 0.194) were similar between years. Completion of genetic testing increased from 204 (46.5%) in 2019 to 338 (63.3%) in 2021 (p < 0.01) with the universal counseling protocol. Specifically, genetic testing completion increased significantly in older patients (p = 0.041) and patients receiving Medicare benefits (p = 0.005). The overall pathogenic variants found increased from 32 to 39 with the most common including BRCA2 (n = 11), CFTR (n = 9), CHEK2 (n = 8), BRCA1 (n = 6).

conclusionUniversal genetic counseling was related to a significant increase in genetic testing completion and an increase in pathogenic variants found among breast cancer patients, specifically in subpopulations which may have been previously excluded by traditional NCCN genetic testing screening guidelines.

Indexed as

Breast NeoplasmsGenetic CounselingGenetic TestingAdultAgedBRCA1 ProteinBRCA2 ProteinCheckpoint Kinase 2FemaleGenetic Predisposition to DiseaseHumansMiddle AgedBRCA1 ProteinBRCA2 ProteinCheckpoint Kinase 2CHEK2 protein, humanAccessibilityBreast cancerGenetic counselingGeneticsUniversal

Identifiers

PMID38822953

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.